Tratamento e manejo clínico das candidíases: uma breve revisão da literatura
DOI:
https://doi.org/10.18378/rebes.v14i3.10540Palabras clave:
Antifúngicos, Micologia, FarmacologiaResumen
As espécies de Candida são comensais e, portanto, fazem parte da flora humana normal e estão localizadas na pele e nos tratos gastrointestinal e genital. No entanto, também pode causar várias infecções em pacientes suscetíveis, incluindo pacientes idosos, hospitalizados ou imunossuprimidos. Este trabalho buscou avaliar o atual cenário dos tratamentos antifúngicos disponíveis para cada tipo de candidíase com enfoque nas características de cada uma das condutas clínicas e suas limitações. Além disso, apresenta novas perspectivas no desenvolvimento de novos compostos com atividade antifúngica e os desafios para a expansão das alternativas terapêuticas disponíveis atualmente. Para tanto foram realizadas buscas nas bases de dados: Scielo, Pubmed e Google acadêmico no período entre fevereiro e maio de 2024. Foram usadas as palavras-chave: Antifungals, candidiasis classification, invasive candidiasis e new antifungals treatments. A infecção invasiva por Candida é uma das infecções fúngicas mais comuns em todo o mundo e são apontadas como uma das principais causas de infecções associadas à saúde. Além disso, o arsenal terapêutico contra a candidíase inclui basicamente quatro classes de antifúngicos: polienos, azóis, equinocandinas e a flucitosina, cada uma delas apresentando problemas que limitam seu uso clínico. Sendo assim, é essencial identificar mecanismos bioquímicos exclusivos para os fungos como alvos de descoberta de drogas, a fim de desenvolver outras gerações de terapias antifúngicas.
Descargas
Citas
AHMADI, A., MOHAMMADNEJADI, E., KARAMI, P., & RAZZAGHI-ASL, N. Current status and structure activity relationship of privileged azoles as antifungal agents (2016–2020). International Journal of Antimicrobial Agents, v. 59, n. 3, p. 106518, 2022.
AKASH, PATIL.; SOUMYAJIT, MAJUMDAR. Echinocandins in antifungal pharmacotherapy, Journal of Pharmacy and Pharmacology, v. 69, n. 12, p. 1635–1660, 2017.
ALDHOLMI, M. et al. A decade of antifungal leads from natural products: 2010–2019. Pharmaceuticals, v. 12, n. 4, p. 182, 2019.
ANTINORI, S. et al. Candidemia and invasive candidiasis in adults: A narrative review. European journal of internal medicine, v. 34, p. 21-28, 2016.
ATALLAH, A.; CASTRO, N. Aldemar Araujo. Revisão sistemática da literatura e metanálise. Medicina baseada em evidências: fundamentos da pesquisa clínica. São Paulo: Lemos-Editorial, p. 42-48, 1998.
BECK, K. R.; ODERMATT, A. Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess. Molecular and Cellular Endocrinology, v. 524, p. 111168, 2021.
BENITEZ, L. L.; CARVER, P. L. Adverse effects associated with long-term administration of azole antifungal agents. Drugs v. 79, n. 8, p. 833–53, 2019.
FERNANDES, M. C.; DASILVA, D.; HARANAHALLI, K.; MCCARTHY, J. B.; MALLAMO, J.; OJIMA, I.; DEL POETA, M. The Future of Antifungal Drug Therapy: Novel Compounds and Targets. Antimicrob Agents Chemother. v. 65, n. 2, p. 10.1128/aac. 01719-20, 2021.
GÓMEZ-LÓPEZ A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clinical Microbiology and Infection, v. 26, n. 11, p. 1481-1487, 2020.
GONZALEZ-LARA, M. F.; OSTROSKY-ZEICHNER, L. Invasive Candidiasis. Seminars in respiratory and critical care medicine. Thieme Medical Publishers, 2020. p. 003-012.
HOENIGL, M.; SPRUTE, R.; EGGER, M.; ARASTEHFAR, A.; CORNELY, O. A.; KRAUSE, R.; LASS-FLÖRL, C.; PRATTES, J.; SPEC, A.; THOMPSON, G. R.; WIEDERHOLD, N.; JENKS, J. D. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. v. 81, n. 15, p. 1703-1729, 2021.
JOHNSON, M. D. Antifungals in Clinical Use and the Pipeline. Infectious Disease Clinics, v. 35, n. 2, p. 341-371, 2021.
LEE, H,; LEE, D. G. Novel Approaches for Efficient Antifungal Drug Action. Jounal Microbiol Biotechnol. 2018
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Flucytosine. [Updated 2018 Feb 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548624/
LOGAN, A.; WOLFE, A.; WILLIAMSON, J.C. Antifungal Resistance and the Role of New Therapeutic Agents. Current Infectious Disease Reports, v. 24, n. 9, p. 105-116, 2022.
LÓPEZ-MARTÍNEZ, R. Candidosis, a new challenge. Clinics in dermatology, v. 28, n. 2, p. 178-184, 2010.
MAZU, K. T.; BRICKER, A. B.; FLORES-ROZAS, H.; ABLORDEPPEY, Y. S. The mechanistic targets of antifungal agents: an overview. Mini reviews in medicinal chemistry, v. 16, n. 7, p. 555-578, 2016.
MCCARTY, TODD P.; PAPPAS, PETER G. Invasive candidiasis. Infectious Disease Clinics, v. 30, n. 1, p. 103-124, 2016.
MCCARTY, TODD P.; WHITE, CAMERON M.; PAPPAS, PETER G. Candidemia and invasive candidiasis. Infectious Disease Clinics, v. 35, n. 2, p. 389-413, 2021.
MOHAMED, A. A.; LU, X. L.; MOUNMIN, F. A. Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. Canadian Journal of Gastroenterology and Hepatology, v. 2019, 2019.
PADDA, I. S.; PARMAR, M. Flucytosine. [Updated 2023 Jan 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024.
PAIVA, J. A.; PEREIRA, J. M. Treatment of invasive candidiasis in the era of Candida resistance. Current Opinion in Critical Care v. 29, n. 5, p. 457-462, 2023.
PAPPAS, P. G.; KAUFFMAN, C. A.; ANDES, D. R et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases, v. 62, n. 4, p. e1-e50, 2016.
PAPPAS, P.; LIONAKIS, M.; ARENDRUP, M. et al. Invasive candidiasis. Nature Reviews Disease Primers, v. 4, n. 1, p. 1-20, 2018.
PIANALTO, K. M.; ALSPAUGH, J. A. New horizons in antifungal therapy. Journal of Fungi, v. 2, n. 4, p. 26, 2016.
QUILES-MELERO, I.; GARCÍA-RODRÍGUEZ, J. Antifúngicos de uso sistémico [Systemic antifungal drugs]. Revista Iberoamericana de Micología, v. 38, n. 2, p. 42-46, 2021.
RAMPONE, S.; PAGLIARULO, C.; MARENA, C.; ORSILLO, A.; IANNACCONE, M.; TRIONFO, C.; SATERIALE, D.; PAOLUCCI, M. In silico analysis of the antimicrobial activity of phytochemicals: towards a technological breakthrough. Comput Methods Programs Biomed. v. 200, p. 105820, 2021.
SAWANT, B.; KHAN, T. Recent advances in delivery of antifungal agents for therapeutic management of candidiasis. Biomedicine & Pharmacotherapy, v. 96, p. 1478-1490, 2017.
SCORZONI, L.; FUCHS, B. B.; JUNQUEIRA, J. C.; MYLONAKIS, E. Current and promising pharmacotherapeutic options for candidiasis. Expert opinion on pharmacotherapy, v. 22, n. 7, p. 887-888, 2021.
SIGERA, L. S. M.; DENNING, D. W. Flucytosine and its clinical usage. Therapeutic advances in infectious disease, v. 10, p. 20499361231161387, 2023.
SOUSA, F.; NASCIMENTO, C.; FERREIRA, D.; REIS, S.; COSTA, P. Reviving the interest in the versatile drug nystatin: A multitude of strategies to increase its potential as an effective and safe antifungal agent. Advanced Drug Delivery Reviews, p. 114969, 2023.
STEIMBACH, L. M. et al. Efficacy and safety of amphotericin B lipid‐based formulations—A systematic review and meta‐analysis. Mycoses, v. 60, n. 3, p. 146-154, 2017.
SZYMAŃSKI, M.; CHMIELEWSKA, S.; CZYŻEWSKA, U.; MALINOWSKA, M.; TYLICKI, A. Echinocandins - structure, mechanism of action and use in antifungal therapy. Journal of Enzyme Inhibition and Medicinal Chemistry, v. 37, n. 1, p. 876-894, 2022.
TORTORANO, A. M.; PRIGITANO, A.; MORRONI, G.; BRESCINI, L.; BARCHIESI, F. Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches. Infection and Drug Resistance, p. 5543-5553, 2021.
TVERDEK, F. P.; KOFTERIDIS, D.; KONTOYIANNIS, D. P. Antifungal agents and liver toxicity: a complex interaction. Expert Review of Anti-Infective Therapy, v. 14, n. 8, p. 765-776, 2016.
WOŹNIAK, M. Antifungal agents in wood protection—A review. Molecules, v. 27, n. 19, p. 6392, 2022.
ZHU, P.; LI, Y.; GUO, T.; LIU, S.; TANCER, R. J.; HU, C.; ZHAO, C.; XUE, C.; LIAO, G. New antifungal strategies: Drug combination and co-delivery. Advanced Drug Delivery Reviews. p. 114874, 2023.
ZIDA, A.; BAMBA, S.; YACOUBA, A.; OUEDRAOGO-TRAORE, R.; GUIGUEMDÉ, R. T. Anti-Candida albicans natural products, sources of new antifungal drugs: A review. Journal de mycologie medicale, v. 27, n. 1, p. 1-19, 2017.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 José Roberto Dantas de Andrade Santos, Edeltrudes de Oliveira Lima, José Lucas Ferreira Marques Galvão, Abrahão Alves de Oliveira Filho
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Termo de cess